Abstracts tagged "SLE and cardiovascular disease"

Abstract Number: 764 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease in SLE at One Center between 1981 and 2016. a Population-Based Study Highlighting the Importance of Disease Duration and Age at Diagnosis
Ola Nived¹, Ragnar F Ingvarsson¹, Anna Jöud², Petrus Linge¹, Helena Tydén¹, Anders A. Bengtsson¹ and Andreas Jönsen¹, ¹Rheumatology, Lund University, Department of Clinical Sciences, Lund, Sweden, ²Division of Occupational and Environmental Medicine, Lund University, Department of Laboratory Medicine, Lund, Sweden
Background/Purpose: Active inflammatory processes characterize early SLE disease, while later morbidity to a considerable extent consists of consequences of organ damage, particularly cardiovascular disease (CVD).…
Abstract Number: 690 • 2017 ACR/ARHP Annual Meeting
SSA Antibodies Are Associated with Valvular Abnormalities in SLE Patients without Clinical Cardiovascular Disease
Elizabeth George¹, Thania Perez², Anca Askanase³ and Laura Geraldino-Pardilla⁴, ¹Rheumatology, Columbia University College of Physicians and Surgeons, New york, NY, ²Columbia University College of Physicians & Surgeons, New York, NY, ³Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Columbia University, New york, NY
Background/Purpose: Cardiovascular involvement including pericardium, conduction system, coronary arteries and valvular abnormalities are frequent manifestations of SLE. It is estimated to occur in more than…
Abstract Number: 985 • 2017 ACR/ARHP Annual Meeting
Heart Failure Hospitalizations Among SLE and Diabetes Mellitus Patients Compared to the General U.S. Medicaid Population
Sarah Chen¹, Medha Barbhaiya², Michael A. Fischer³, Hongshu Guan⁴, Candace H. Feldman⁵, Brendan M. Everett⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is increased in SLE patients, compared to the general population and age- and sex-matched diabetes mellitus (DM) patients. Heart failure…
Abstract Number: 1632 • 2017 ACR/ARHP Annual Meeting
SLE Characteristics Associated with Modified Framingham Risk Score in Patients without Clinical Cardiovascular Disease
Elizabeth George¹, Thania Perez², Nelson Perez³, Anca Askanase⁴ and Laura Geraldino-Pardilla⁵, ¹Rheumatology, Columbia University College of Physicians and Surgeons, New york, NY, ²Columbia University College of Physicians & Surgeons, New York, NY, ³Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago, Dominican Republic, ⁴Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁵Columbia University, New york, NY
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in SLE and identifying those at risk remains challenging. While in the general population the…
Abstract Number: 2044 • 2017 ACR/ARHP Annual Meeting
Secondary Prevention of Cardiovascular Disease Is Incomplete in a Systemic Lupus Erythematosus Population-Based Cohort
Suzana John¹, Cristina Drenkard², Gaobin Bao² and S. Sam Lim², ¹Rheumatology, Emory University, Atlanta, GA, ²Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Cardiovascular disease (CVD) is a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). We know that a combination of traditional cardiovascular…
Abstract Number: 1303 • 2016 ACR/ARHP Annual Meeting
Extended T2-Times in Cardiovascular Magnetic Resonance (CMR) in Patients with Systemic Lupus Erythematosus (SLE) and Persisted Dyspnoea: Is SLE-Associated Myocarditis an Underestimated Problem?
Dr. Philipp Sewerin¹, Vera Lachmann², Mareike Gastl², Patrick Behm³, PD Dr. Rebecca Fischer-Betz⁴, Prof. Dr. Benedikt Ostendorf¹, Dr. Gamal Chehab⁵, Prof. Dr. Matthias Schneider¹, Prof. Dr. Malte Kelm² and Dr. Florian Bönner², ¹Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany, ²Department of Internal Medicine, Division of Cardiology, Pulmology and Vascular Medicine and Molecular Cardiology, Heinrich-Heine University, Düsseldorf, Germany, ³Heinrich-Heine University, Düsseldorf, Germany, ⁴Department of Rheumatology & Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, ⁵Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, 40225 Duesseldorf, Germany
Background/Purpose: To investigate the value of cardiovascular magnetic resonance (CMR) and T2-mapping in patients with systemic lupus erythematosus (SLE) and persistent dyspnoea without sings for…
Abstract Number: 1068 • 2015 ACR/ARHP Annual Meeting
Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE
Michelle Petri¹ and Laurence S Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
B Background/Purpose: In 2013 the American College of Cardiology (ACC) and the American Heart Association (AHA) developed a new formula to estimate the 10-year risk…
Abstract Number: 1794 • 2015 ACR/ARHP Annual Meeting
Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients
Michelle Petri¹ and Laurence S Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We have observed a decline in rates of cardiovascular events in systemic lupus erythamatosus (SLE) pateints in our clinic. In this work presented below,…
Abstract Number: 2790 • 2014 ACR/ARHP Annual Meeting
CMR with Quantitative T2 Mapping in Patients with Active SLE
Stacy P. Ardoin¹, Wael N. Jarjour², Subha V. Raman², Amanda Kibler² and Tam Tran², ¹Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ²Ohio State University, Columbus, OH
Background/Purpose: Cardiovascular (CV) disease is an important cause of morbidity in systemic lupus erythematosus (SLE) . Myocarditis is considered an uncommon complication of SLE…
Abstract Number: 705 • 2014 ACR/ARHP Annual Meeting
Lupus Chest Pain in the Emergency Department: a Common Diagnostic Dilemma
Masoom Modi¹, Mariko L. Ishimori¹, Daniel J. Wallace² and Michael Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Chest pain (CP) is a common symptom reported by SLE patients often leading to presentation to Emergency Departments (ED). The origin of CP…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].